Nanog is a transcription factor required for maintaining the pluripotency of embryonic stem cells, and is not expressed in most normal adult tissues. However, recent studies have indicated that Nanog is overexpressed in many types of human cancers, including breast cancer. To elucidate the physiological roles of Nanog in tumorigenesis, we developed an inducible Nanog transgenic mouse model, in which the expression of Nanog in adult tissues can be induced via LoxP/Cre-mediated deletion. Our findings indicate that overexpression of Nanog in the mammary gland is not sufficient to induce mammary tumor. However, when coexpressed with Wnt-1 in the mouse mammary gland, it promotes mammary tumorigenesis and metastasis. In this context, Nanog promotes the migration and invasion of breast cancer cells. Microarray analysis has shown that the ectopic expression of Nanog deregulates the expression of numerous genes associated with tumorigenesis and metastasis, such as the PDGFRa gene. Our findings demonstrate the involvement of Nanog in breast cancer metastasis, and provide the basis for the reported correlation between Nanog expression and poor prognosis of human breast cancer patients. As Nanog is not expressed in most adult tissues, these findings identify Nanog as a potential therapeutic target in the treatment of Nanog-expressing metastatic breast cancer.
INTRODUCTION
Breast cancer is the most common malignancy in women worldwide. 1 Although the mortality rate of breast cancer patients has decreased due to more effective early detection, resistance to conventional treatment, recurrence and metastasis still remain as common problems for breast cancer patients with poor prognoses. Some embryogenesis-associated genes associated with the Wnt, 2 Hedgehog 3 and Notch pathways 4, 5 are frequently overexpressed in human cancers, and have been shown to induce the initiation and metastasis of cancer.
The transcription factors Oct4, Sox2 and Nanog are all required for maintaining the pluripotency of embryonic stem cells (ESCs). [6] [7] [8] [9] Constitutive overexpression of Nanog suppresses the differentiation of ESCs induced by various stimuli, such as retinoic acid or withdrawal of leukemia inhibitory factor. 6 In addition, the targeted disruption of Nanog in ESCs leads to rapid differentiation. 7 
Nanog
þ / À ESCs are also prone to spontaneous differentiation, further indicating the importance of Nanog in maintaining selfrenewal in ESCs. 10 These findings indicate that Nanog is required and sufficient to maintain the pluripotency and self-renewal of ESCs. Moreover, Nanog induces fetal liver kinase-1 expression and regulates angiogenesis during embryonic development. 11 Normally, Nanog is exclusively expressed in early embryonic stages and in germline stem cells; it is not expressed in adult tissues. 6, 7, 10 Similarly, Oct4 is expressed primarily in pluripotent cells, including epiblasts and germline stem cells, but not in most somatic cells. [12] [13] [14] However, Nanog and Oct4 are expressed at high levels in multiple types of cancers, including breast cancer. [15] [16] [17] [18] [19] Recent studies of cancer cell lines overexpressing Nanog and Oct4 have shown that double knockdown of Oct4 and Nanog reverses the epithelial-mesenchymal transition (EMT) process, inhibiting the metastasis of lung adenocarcinoma cells. 19 In ovarian cancer, Nanog regulates cell migration and invasion via dysregulation of E-cadherin and FoxJ1. 20 These results suggest that Nanog has oncogenic activities. 19 However, the proposed roles of Nanog in oncogenesis are based largely on the circumstantial evidence of overexpression in tumors and cell line models.
To investigate the physiological roles of Nanog in promoting tumorigenesis, we established a conditional Nanog transgenic mouse model to allow the inducible expression of Nanog. Our findings elucidate that Nanog is not an initiating factor for mammary tumorigenesis, but it can promote mammary tumorigenesis and metastasis when activated with other oncogenes.
RESULTS

Induced expression of Nanog in the mouse mammary epithelium
To determine the impact of Nanog expression on mammary tumorigenesis, we generated transgenic mice for the conditional expression of Nanog, denoted TNanog mice ( Figure 1a) . The presence of a LoxP-flanked transcription stop signal between the chicken beta-actin promoter/enhancer and the Nanog complementary DNA (cDNA) enables inducible and tissue-specific expression of Nanog via LoxP/Cre-mediated deletion of the stop signal sequence. To ectopically express Nanog in the mammary gland, TNanog mice were bred with mouse mammary tumor virus-Cre (MMTV-Cre) transgenic mice that express Cre in mammary epithelial cells (MECs), including mammary epithelial stem cells. 21 We confirmed that Nanog is expressed in the MECs of TNanog/MMTV-Cre mice, denoted TN mice (Figures 1b, c, and Supplementary Figure S1 ). In addition, we showed that Nanog was expressed in mammary basal epithelial cells (Supplementary Figure S2a) . The TN mice did not spontaneously develop mammary tumors for up to 2 years of age, indicating that expression of Nanog alone is not sufficient to induce mammary tumorigenesis ( Figure 2a ).
Nanog accelerates mammary tumorigenesis in MMTV-mWnt-1 mice It has been shown that Nanog is overexpressed in several types of human cancers, including breast cancer, suggesting that it may have an important role in the development and progression of breast cancer. To determine the roles of Nanog in mammary tumorigenesis, we crossed MMTV-Wnt-1 (denoted mWnt-1) transgenic mice with TNanog/MMTV-Cre mice to produce TNanog/MMTV-Cre/MMTV-Wnt-1 (denoted TNW) mice. We confirmed that Nanog was expressed in the MECs of TNW mice, including Lin À CD24 þ CD29 hi mammary epithelial stem cells (Supplementary Figure S2b) . Wnt-1 is commonly overexpressed in human breast cancer, and its ectopic expression in the mouse mammary gland of MMTV-Wnt-1 transgenic mice is sufficient to induce mammary tumors. 22 To monitor mammary tumorigenesis, virgin female TNW, MMTV-Cre/mWnt-1 and mWnt-1 mice were visually inspected twice a week. The median survival time for female TNW mice was 147.5 days; significantly shorter than that of MMTV-Cre/mWnt-1 or mWnt-1 mice (187.5 and 194 days, respectively), indicating that Nanog expression accelerated mammary tumorigenesis. This was not due to the expression of Cre in the MECs, because there was no significant difference in the survival time between MMTV-Cre/mWnt-1 and mWnt-1 mice (Figure 2b ). The number of tumors per mouse developed in TNW mice and control mice was not significantly different (data not shown). The mammary tumors derived from TNW mice were welldifferentiated adenocarcinomas that were histologically indistinguishable from the mammary tumors found in mWnt-1, TNanog/ mWnt-1 or MMTV-Cre/mWnt-1 mice (Supplementary Figure S3) .
Whole-mount analysis of premalignant mammary glands of TNW mice showed increased numbers of terminal branches,
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Anti-Nanog suggesting hyperplasia (Figure 2c ). To quantify the degree of hyperplasia, sections of mammary glands from 2-month-old mice were stained with hematoxylin and eosin, scanned and analyzed to determine the epithelial content. We found that the epithelial content of mammary glands of female TNW mice was significantly higher than that of age-matched MMTV-Cre/mWnt-1 control mice ( Figure 2d ). Therefore, when ectopically expressed in MECs, Nanog co-operates with Wnt-1 to induce hyperplasia and accelerate mammary tumorigenesis.
Nanog promotes mammary tumor metastasis Previous studies have shown that Nanog can promote cell migration and invasion in lung cancer and ovary cancer, indicating Nanog might promote cancer metastasis. To evaluate this function of Nanog in mammary cancer cells, acroscopic metastases in the lung, liver, spleen and kidney were detected following necropsy. We found that the mammary tumors that developed in the TNW mice were highly metastatic and often spread to other tissues such as lung, liver and kidney. We found that mammary tumors had spread to the lung in 64% of the TNW mice, significantly higher than in the mWnt-1 (16.7%), TNanog/mWnt-1 (15.8%) or MMTV-Cre/mWnt-1 (18.4%) mice (Figures 3a and b) . Histologically, the metastatic lung cancers were typical mammary adenocarcinomas ( Figure 3c ). The continued expression of Nanog in the majority of primary mammary tumors and their metastatic counterparts in TNW mice further supports the notion that Nanog promotes tumorigenesis and metastasis (Figure 3d ). 
Expression of Nanog in mammary tumor cells promotes migration and invasion
Metastasis depends on the capability of cancer cells to acquire a migratory phenotype combined with their capacity to create a secondary tumor in a distant tissue. 23 To explore the impact of Nanog on the migration and invasion ability of mammary tumor cells, we isolated primary mammary tumor cells from mammary tumors developed in the TNanog/mWnt-1 mice, and induced Nanog expression by transducing them with lentivirus expressing Cre recombinase (Figure 4a ). To examine the roles of Nanog in promoting tumor metastasis, we tested the impact of Nanog expression on cancer cell migration using transwell migration and invasion assays, which are widely used to study the processes of cell migration and invasion. The results indicate that Nanog promoted mammary tumor cell migration and invasion (Figures 4b-d ) Here, we used primary mammary tumor cells to confirm that Nanog can promote migration and invasion of mammary tumor cells.
Expression of Nanog enhances growth and invasion of human breast cancer cells To test whether Nanog has the same oncogenic function in human breast cancer cells, we expressed human NANOG in the human breast cancer cell line MCF7 (Figure 5a ). Previous reports on the endogenous expression of NANOG in MCF7 cells have been controversial; one found it to be highly expressed, 11 while the other reported only low levels of expression. 24 Using quantitative PCR (qPCR), we found the basal level of NANOG mRNA in MCF7 to be much lower than that in human ESCs (Supplementary Figure S4a) ; however, after transduction with a NANOG-expressing lentivirus, NANOG expression was B4000-fold higher than in mock-treated MCF7 control cells (Supplementary Figure S4b) . Using a soft agar assay, we found that overexpression of NANOG enhanced colony formation of MCF7 cells (Figure 5b ). Consistent with the conclusions from mouse models, overexpression of NANOG promoted migration and invasion of MCF7 cells (Figures 5c and d) . To test the impact of NANOG on the tumorigenesis and metastasis of human breast cancer cells, we orthotopically transplanted MCF7 cells with or without NANOG expression into the second mammary glands of severe combined immunodeficiency (SCID) mice. We found that the overexpression of NANOG promoted human breast tumor growth in SCID mice (Figures 5e and f), and the tumors formed by NANOG-overexpressing MCF7 cells exhibited invasive characteristics (Figure 5g ). These data demonstrated that Nanog has conserved functions in promoting breast cancer in both humans and mice. Nanog deregulates the expression of genes that are associated with tumorigenesis and metastasis To gain further insight into the mechanism by which Nanog promotes mammary tumor tumorigenesis and metastasis, we compared the patterns of gene expression in mammary tumors from control (MMTV-Cre/mWnt-1) and TNW mice. Three tumors from Nanog-overexpressing mice exhibited high-Nanog probe intensity, and were used for further analysis in comparison with six control tumor samples. We identified 112 probes corresponding to 106 genes whose levels differed significantly (nominal Po0.05) and substantially (fold-change 41.4) between the high-Nanog-expressing tumors and the control tumors (Figure 6a , Supplementary Table  S1 ). Of these, 62 genes (58%) were more highly expressed in the high-Nanog-expressing tumors, and 44 genes were expressed at lower levels than in control tumors. The EMT marker fibronectin was found highly expressed in the high-Nanog-expressing tumors in the microarray assay (Supplementary Table S1 ). Interestingly, we found the PDGFRa gene to be upregulated in Nanog-overexpressing breast cancers. The product of the PDGFRa gene, a growth factor receptor tyrosine kinase, is a driver of tumorigenesis, angiogenesis and metastasis in a variety of cancers. 25 The activation of PDGFRa was shown to be involved in cell survival during EMT and in experimental metastasis in mice. 26 PDGFRa was recently identified as one of the direct targets of Twist-1, mediating invadopodia formation in response to various EMT-inducing signals. 27 Our qPCR results confirmed that the PDGFRa gene is upregulated in high-Nanogexpressing breast cancers compared with the MMTV/Cre-mWnt-1 breast cancers (Figure 6b) . Moreover, the regulation of PDGFRa expression is conserved, as it is also highly expressed in NANOGexpressing MCF7 cells relative to control MCF7 cells (Figure 6c ). These data suggest that Nanog might induce expression of PDGFRa to promote mammary tumor tumorigenesis and metastasis. Further evidence supporting this view is the existence of a Nanog binding site in the promoter region of the PDGFRa gene. 28, 29 Further analysis of the differentially expressed genes suggests that genes that exhibit at least 1.8-fold higher expression in the high-Nanog-expressing breast tumors than in the control breast tumors are likely to be associated with two characteristics: first, a high-Nanog transcription factor association score in ES cells 30, 31 and second, a bivalent promoter that displays both histone H3 lysine 4 trimethylation (H3K4me3) and H3 lysine 27 trimethylation (H3K27me3) modifications 32 (Supplementary Table S1 ; Supplementary Figure S6 ). To further characterize the effects of Nanog overexpression in mammary tumors, we subjected the expression data set to gene set enrichment analysis using gene sets representing the Kyoto encyclopedia of genes and genomes (KEGG) canonical pathways. 33 Out of 148 gene sets, eight pathways were significantly enriched (nominal P-value o0.05) in the high-Nanog-expressing tumors, and seven pathways were significantly enriched in the control samples (Supplementary Table S2 ). The pathways significantly enriched in the Nanog-expressing tumor samples included those involved in the extracellular matrix receptor interactions, chemokine signaling and cell and focal adhesion pathways, consistent with the increased tendency of the cells to metastasize (Figure 6d ). In addition, several other genes differentially affected by Nanog expression have been implicated in tumorigenesis and metastasis. For example, transgelin3, sema3c and Rio-1 exhibit increased expression in the high-Nanog tumor samples. Increased levels of semaphorin 3C expression have been associated with increased invasiveness. 34 The specific cleavage of semaphorin 3C by a metalloprotease permits its release from the extracellular matrix and promotes the migration of breast cancer cells. 35 Transgelin has been shown to be associated with a specific subpopulation of actin filament bundles that form podosomes, and be involved in cell migration. 36 Using qPCR, we confirmed the higher expression of these genes in high-Nanog-expressing mammary tumor than in control mammary tumor (Supplementary Figure S5a) . In addition, similar pattern of differential expression of these genes was found in the mammary cells of TNW and control mice before apparent tumorigenesis, supporting the notion that the deregulated expression of these genes is mediated by overexpressed Nanog (Supplementary Figures S5b and S7 ).
DISCUSSION
A number of core transcription factors, including Nanog, Oct4 and Sox2, are required to maintain the pluripotency of mouse and human ESCs. Recent findings have shown that the homedomain pluripotency factor Nanog is overexpressed in poorly differentiated breast cancers, and its expression correlated with poor prognosis in breast cancer patients. 37 To investigate the function of Nanog in the initiation and progression of breast cancer, we generated conditional Nanog-expressing transgenic mice. We found that overexpression of Nanog in MECs alone is not sufficient to induce mammary tumors in mice. However, ectopic expression of Nanog in the mammary glands of mWnt-1 transgenic mice accelerates mammary tumorigenesis and promotes metastasis.
Owing to the chimeric expression of Cre in MMTV-Cre transgenic mice, the impact of Nanog on the mammary tumorigenesis may be underestimated in our system. In summary, our findings clearly indicate that Nanog is not an initiating factor for mammary tumorigenesis, but when ectopically expressed in MECs together with the Wnt-1 oncogene, it promotes mammary tumorigenesis and metastasis. In addition to Nanog1 used in this study, recent studies have suggested that NanogP8, a NANOG pseudogene that could encode a functional protein, is frequently overexpressed in cancer cells. [38] [39] [40] In MCF7 cells, overexpression of Nanog1 or NanogP8 was found to promote cancer stem cell characteristics. 41, 42 Using qPCR, Jeter et al. 41, 42 also identified several prosurvival/ detoxification genes upregulated by NANOG1/NANOGP8, including Bcl-2, ABCG2, CD133 and ALDH1A1. Although we found that PDGFRa is highly expressed in Nanog-overexpressing mammary tumor cells, we did not detect the overexpression of Bcl-2, ABCG2, CD133 and ALDH1A1 in our microarray data. This discrepancy could be due to the species difference or that the sample we used for gene profile analysis is mammary tumor instead of cultured cell lines. NanogP8 encodes a protein that differs from Nanog by a single amino acid, (Q253H). 41, 42 Therefore, the function of NanogP8 gene product in promoting tumorigenesis in vivo could be similar to that of Nanog.
The EMT program is a highly conserved developmental program that promotes epithelial cell dissociation and migration to distant sites during embryogenesis. In malignant tissues, cells undergoing the EMT acquire cellular traits associated with high-grade malignancy, including motility, invasiveness and increased resistance to apoptosis. 43 Recent studies have indicated that the EMT program can drive both normal and neoplastic MECs to enter into a stem cell-like state. 44, 45 Additionally, it was found that the coexpression of Nanog and OCT4 promotes the EMT and enhances cancer stem-like properties in lung adenocarcinoma cells. 19 In MCF7 cells, overexpression of Nanog1 or NanogP8 was found to promote cancer stem cell characteristics. 42 Consistent with previous findings, our data indicate that PDGFRa is highly expressed in Nanogoverexpressing mouse mammary tumor cells as well as human breast cancer cell line. These results indicate that PDGFRa might be an evolutionarily conserved Nanog target gene. The overexpression and activation of PDGFRa have been observed in aggressive human breast cancers. 26 The activation of PDGFRa was also shown to be involved in cell survival during the EMT and experimental metastasis in mice. 26 Recently, PDGFRa was identified as one of the direct targets of Twist-1, mediating invadopodia formation in response to various EMT-inducing signals. Previously reported ChIP-Seq data also showed that Nanog binds the promoter of PDGFRa, indicating that PDGFRa is a direct target of Nanog. 28 In addition, several additional genes that regulate tumorigenesis and metastasis were upregulated in the mammary tumors with Nanog overexpression. Most of these genes have a Nanog binding motif in their promoter regions, which exhibit both H3K4me3 and H3K27me3 modifications, a characteristic of genes 'poised' for expression (Supplementary  Table S1 and Supplementary Figure S6) . Therefore, our findings indicate that Nanog might act as a transcription factor in breast cancer, and regulate gene expression to promote mammary tumorigenesis and metastasis.
MATERIALS AND METHODS
Generation and characterization of TNanog and TNanog-derived mice
The LoxP-flanked Neo-STOP cassette (about 2.8 Kb), 46 and the entire Nanog coding sequence were sequentially inserted downstream of the chicken beta-actin promoter and upstream of the SV40Poly-A sequence (Figure 1a) . The vector DNA was purified and injected into the oocytes to generate transgenic mice. The primers used for TNanog mice genotyping are P1: 5 0 -TTCTGGCGTGTGACCGGCG-3 0 , P2: 5 0 -CCTCTATCGCCT TCTTGACGA-3 0 and P3: 5 0 -CTTCCTCAGAACTAGGCAAACTG-3 0 (Figure 1a ). To generate TN mice, we crossed TNanog mice with MMTV-Cre mice (NCI Mouse Repository, Frederick, MD, USA). To generate the TNW mice, we bred female TN mice with male mWnt-1 mice. 22 
Lung metastases's macroscopic analysis
The TNW, TNanog/mWnt-1, MMTV-Cre/mWnt-1 and mWnt-1 mice were killed when primary mammary tumors grew to 1.5 cm in diameter. The number of macroscopic lung metastases was detected following necropsy. Animals with at least one macroscopic metastatic clone found in the lung were counted as lung metastases positive.
Isolation and culture of primary mammary tumor cells
Primary mammary tumor cells were isolated as previously described. 47 Breast tumors were harvested when they reached 1.5 cm in diameter, minced with a razor blade and suspended into 20 ml of medium 199 (Gibco, Life Technologies, Grand Island, NY, USA) with 20 mM Hepes buffer. One hundred Kunitz units of DNase (Stemcell Technologies, Vancouver, BC, Canada), 8 Wü nsch U of Liberase Blendzyme research grade TM (Roche, Applied Science, Indianapolis, IN, USA) and 8 Wü nsch U of Liberase Blendzyme research grade TH (Roche, Applied Science) were added. The samples were incubated for 2 h at 38 1C with pipetting through a 10-ml pipette every 30 min for manual dissociation. Following digestion, 80 ml of RPMI 1640 (Life technologies) with 10% fetal bovine serum was used to filter the sample through a 40-mm cell strainer (BD Biosciences, San Jose, CA, USA). The cells were spun at 1500 r.p.m. for 5 min. The cell pellet was resuspended in 0.64% NH 4 Cl for 3 min. The cells were washed and cultured in complete growth media containing 5 mg/ml insulin, 1 mg/ml hydrocortisone (SigmaAldrich, St Louis, MO, USA), 3 ng/ml epidermal growth factor, 10% fetal bovine serum (Hyclone, South Logan, UT, USA), 50 U/ml penicillin/streptomycin in Dulbecco's modified Eagle medium/F12 (Gibco, Life Technologies). All the cultures were maintained at 37 1C in a humidified 5% CO 2 atmosphere.
Cell culture
The MCF7 cell line was obtained from ATCC (Manassas, VA, USA). The base medium for this cell line is ATCC-formulated Eagle's minimum essential medium, complemented with 0.01 mg/ml bovine insulin and 10% fetal bovine serum.
Histology and immunofluorescence analysis
Mammary gland and mammary cancer samples were fixed in 10% buffered formalin, embedded in paraffin and sliced. All of the sections were stained with hematoxylin and eosin for histological assessment as previously described. 48 Rabbit polyclonal antibodies against Nanog (CosmoBio, Carlsbad, CA, USA) and Chicken polyclonal antibodies against Keratin5 (gift from Dr Colin Jamora, UCSD, San Diego, CA, USA) were used for immunofluorescence assay. For the immunofluorescence assay, the mammary tissue was embedded in OCT (Sakura Finetek USA, Torrance, CA, USA) compound and frozen. After fixation in 100% acetone, the sections were rehydrated, blocked with 3% bovine calf serum in phosphate-buffered saline and then incubated with rabbit polyclonal anti-Nanog antibodies (CosmoBio). After washing with 1 Â TBST three times, the sections were incubated with Alexa Fluor 488 donkey anti-rabbit antibodies (Invitrogen, Life Technologies) and Alexa Fluor 568 donkey anti-chicken secondary antibodies (Invitrogen) overnight at 4 1C. After mounting on glass slides with VECTASHIELD mounting media with 4, 6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA, USA), the slides were stored at 4 1C. The images were acquired using an Olympus confocal microscope (Olympus America Inc., Center Valley, PA, USA).
Western blotting analysis
Protein extracts from 4 Â 10 5 MECs were resolved by 12% SDSpolyacrylamide gel electrophoresis, transferred to nitrocellulose membranes and probed with rabbit polyclonal antibodies against Nanog (Bethyl, Montgomery, TX, USA) and Tubulin (Sigma-Aldrich). The membranes were subsequently probed with a horseradish peroxidase-conjugated secondary antibody and developed with SuperSignal West Dura Chemiluminescent Substrate (Thermo, Rockford, IL, USA).
Breast whole-mount preparation Mammary tissue was harvested from euthanized mice. For whole-mount examination, the mammary tissue was fixed in 10% formalin or 4% paraformaldehyde overnight and stained with carmine aluminum (SigmaAldrich) for 24 h. Stained tissues were washed in 70% ethanol, 95% ethanol and 100% ethanol for 1 h each. Then the tissue was cleared in xylene (Fisher Science, Scientific, Hampton, NH, USA) overnight and stored in methyl salicylate (Sigma-Aldrich).
RNA extraction
Total RNA was extracted from cells using a QIAshredder and an RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and cDNA was generated using Applied Biosystem's High Capacity cDNA Reverse Transcription Kit, both according to the manufacturer's protocols.
Expression profiling
For each sample, 250 ng of total RNA was amplified and biotinylated using the TotalPrep RNA Amplification Kit (Ambion, Life Technologies) according to the manufacturer's protocol. cRNA samples were hybridized to Illumina mouse Ref-8 v2.0 gene expression arrays and processed following the manufacturer's protocol. Images were collected using an Illumina BeadArray Reader (Illumina, San Diego, CA, USA). Improved probe annotations were applied, 49 and data from probes classified as 'perfect' or 'good' were retained. After removing the probes that were poorly detected in both classes, 15792 probes remained for further analysis. The expression data sets were normalized by the 'rsn' method of the lumi package in R. 50 Probes indicating differential expression between the two classes were identified by the two-tailed Student's t-test, and were further limited by requiring foldchange ratios greater than 1.4. Analysis of transcription factor binding site overabundance in the promoter regions of selected genes was performed by Nanog promotes tumorigensis and metastasis of breast cancer X Lu et al CisView using the region À 1000 to þ 500 bp relative to the major transcription start site. 51 In addition, gene expression data were analyzed by gene set enrichment analysis using gene set enrichment analysis software and the molecular signature database. 33 Analysis of the presence or absence of Nanog binding motifs in the promoters of differentially expressed genes was performed using CisView (http://lgsun.grc.nia.nih.gov/cisview/). Differentially expressed genes were annotated with the associated Nanog transcription factor association score 30 based on ChIP-seq data from mouse ES cells 31 and with the histone modification class of the promoter. 
HNanog and EGFP-Cre overexpression lentiviral constructs and lentivirus infection
The human Nanog coding sequence was amplified from Hues9 cDNA using the following primers: hNanogF: 5 0 -CCGCTCGAGATGAGTGTGGATCC AGCTTG-3 0 ; hNanogR: 5 0 -ACGCGTCGACTCAAGCGTAATCTGGAACATCGTAT GGGTACACGTCTTCAGGTTGCATGT-3 0 . The resulting product was cloned into the pBluescript SK( þ ) vector, with the internal ribosome entry site (IRES) sequence from PL451 sequentially cloned at the 3 0 end of the hNanog coding sequence. The hNanog-IRES fragment was then subcloned into pLenti CMV GFP Puro (658-5) (Addgene plasmid 17448, Addgene, Cambridge, MA, USA) using XbaI restriction endonuclease digestion. 52 The enhanced green fluorescent protein-Cre (EGFP-Cre) fusion protein coding sequence was amplified from plasmid pIGCN21 (a gift from Dr E-Chiang Lee, the Woodlands, TX, USA) using the primer pair GFP-CreF (5 0 -GCTCTAGAGATAATATGGCCACAACCATG-3 0 ) and GFP-CreR (5 0 -ACGCGT CGACTGATCAGTTATCTAGATCCGGTG-3 0 ). The EGFP-Cre sequence was then cloned into pLenti CMV GFP Puro (658-5) to replace the EGFP coding sequence. The lentivirus vector and packaging vector-psPAX2 (Addgene plasmid 12260) and pMD2.G (Addgene plasmid 12259) were cotransfected into 293T cells using calcium phosphate transfection. Titers of lentiviral preparations were determined using 293T cells and ranged between 10 7 -10 8 IFU/ml. One day before the infection, cells were placed in a six-well plate at a density of 0.1 million cells/well. Lentiviral particles in cell culture medium (200 ml/well) were added in the presence of 5 mg/ml polybrene to initiate infection. The viruses were removed after 12 h, and fresh cell culture medium was added.
